MedPath

Effect of 3-week AT-1 receptor blockade on insulin resistance in relation to endocrine activity of adipose tissue in patients with insulin resistance - Micardis and insulin resistance

Phase 1
Conditions
Metabolic syndrome with impaired glucose homeostasis nad prehypertension
Registration Number
EUCTR2006-000490-29-CZ
Lead Sponsor
Insitute for Clinical and Experimental Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Male
Target Recruitment
15
Inclusion Criteria

Presence of metabolic syndrome according to NCEP AT III and impaired glucose homeostasis
Hypertension, pharmacologically untreated
Age 30 - 65 years
BMI 25 - 35 kg/m2
Patients must be able to complete all planned visits and to finish the study safely according to investigators opinion
Written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Diabetes mellitus
Important internal disease cardiovascular, tumorous or autoimmune
Thyreopathy or other important endocrine disease
Drug or alcohol dependence
Known hypersensitivity to IMP or to substances of similar chemical structure

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To evaluate the effect of telmisartan on insulin resistance measured by hyperinsulinaemic euglycaemic clamp;Secondary Objective: To monitor expressions of selected adipokines in subcutaneous adipose tissue;Primary end point(s): Insulin effect in glucose metabolism, tested by hyperinsulinaemic euglycaemic clamp
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath